American journal of translational research · 2026
Network pharmacology identifies the mechanisms of action of Jianpi Yanggan Pill in treating diarrhea-predominant irritable bowel syndrome.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ma Ke, Hua Xiaokun, Li Zhipeng, Zhang Shenghua, Zhu Ting, Jin Linxi, Li Weiping, Shao Jingran, Li Xiang, Wen Weibo, Luan Yunpeng
Аннотация
OBJECTIVE: To investigate the molecular mechanisms of Jianpi Yanggan Pill (JPYGP) in treating Diarrhea-predominant irritable bowel syndrome (IBS-D) using an integrated network pharmacology approach combined with experimental validation.
METHODS: The chemical constituents of JPYGP were identified by ultra-high performance liquid chromatography-high-resolution mass spectrometry (UHPLC-MS/MS), and bioactive compounds were screened using various databases. Candidate targets was predicted, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment studies. An IBS-D rat model was established using acetic acid enema combined with restraint stress. The therapeutic potential of JPYGP was further validated through biochemical assays, including Western blotting and enzyme-linked immunosorbent assay (ELISA), to assess the involvement of the C-X-C motif chemokine ligand 8 and extracellular signal-regulated kinase (CXCL8-ERK) signaling pathway.
RESULTS: UHPLC-MS/MS analysis identified 2,309 candidate compounds in JPYGP, among which 20 were bioactive. A total of 660 targets were predicted, of which 414 overlapped with IBS-D-related targets. Enrichment analysis highlighted that these targets were mainly involved in inflammatory and MAPK pathways. In a living organism, JPYGP noticeably alleviated diarrhea symptoms and visceral pain, reduced colonic tissue damage, inhibited mast cell activation, and downregulated the expression of CXCL8 and phosphorylated ERK1/2.
CONCLUSION: JPYGP exerts therapeutic effects on IBS-D via a multi-component, multi-target mechanism, primarily by suppressing the CXCL8-ERK pathway, thereby attenuating colonic inflammation and visceral hypersensitivity.
METHODS: The chemical constituents of JPYGP were identified by ultra-high performance liquid chromatography-high-resolution mass spectrometry (UHPLC-MS/MS), and bioactive compounds were screened using various databases. Candidate targets was predicted, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment studies. An IBS-D rat model was established using acetic acid enema combined with restraint stress. The therapeutic potential of JPYGP was further validated through biochemical assays, including Western blotting and enzyme-linked immunosorbent assay (ELISA), to assess the involvement of the C-X-C motif chemokine ligand 8 and extracellular signal-regulated kinase (CXCL8-ERK) signaling pathway.
RESULTS: UHPLC-MS/MS analysis identified 2,309 candidate compounds in JPYGP, among which 20 were bioactive. A total of 660 targets were predicted, of which 414 overlapped with IBS-D-related targets. Enrichment analysis highlighted that these targets were mainly involved in inflammatory and MAPK pathways. In a living organism, JPYGP noticeably alleviated diarrhea symptoms and visceral pain, reduced colonic tissue damage, inhibited mast cell activation, and downregulated the expression of CXCL8 and phosphorylated ERK1/2.
CONCLUSION: JPYGP exerts therapeutic effects on IBS-D via a multi-component, multi-target mechanism, primarily by suppressing the CXCL8-ERK pathway, thereby attenuating colonic inflammation and visceral hypersensitivity.